Role of the Met(287)Thr polymorphism in the AS3MT gene on the metabolic arsenic profile.

[1]  J. G. García Fernández,et al.  Relation between arsenic in drinking water and skin cancer , 1981, Biological Trace Element Research.

[2]  M. Ando,et al.  Intake of arsenic from water, food composites and excretion through urine, hair from a studied population in West Bengal, India. , 2006, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[3]  Eric D. Wieben,et al.  Human Arsenic Methyltransferase (AS3MT) Pharmacogenetics , 2006, Journal of Biological Chemistry.

[4]  R. Marcos,et al.  Metabolic Profile in Workers Occupationally Exposed to Arsenic: Role of GST Polymorphisms , 2006, Journal of occupational and environmental medicine.

[5]  M. Waalkes,et al.  Preventive mechanism of cellular glutathione in monomethylarsonic acid-induced cytolethality. , 2005, Toxicology and applied pharmacology.

[6]  K. Leineweber,et al.  Beta2-adrenoceptor gene polymorphisms. , 2005, Pharmacogenetics and genomics.

[7]  R. Stone,et al.  Acute promyelocytic leukemia: current strategies for the treatment of newly diagnosed disease. , 2005, Clinical advances in hematology & oncology : H&O.

[8]  Lizhi Yu,et al.  Developmentally Restricted Genetic Determinants of Human Arsenic Metabolism: Association between Urinary Methylated Arsenic and CYT19 Polymorphisms in Children , 2005, Environmental health perspectives.

[9]  M. Ando,et al.  Urinary arsenic species in an arsenic-affected area of West Bengal, India (part III) , 2005 .

[10]  F. Lo Coco,et al.  Arsenic trioxide in the treatment of acute promyelocytic leukemia. A review of current evidence. , 2005, Haematologica.

[11]  S. Hirano,et al.  A new metabolic pathway of arsenite: arsenic–glutathione complexes are substrates for human arsenic methyltransferase Cyt19 , 2005, Archives of Toxicology.

[12]  S. Waters,et al.  Interindividual variation in the metabolism of arsenic in cultured primary human hepatocytes. , 2004, Toxicology and applied pharmacology.

[13]  M. Waalkes,et al.  Cellular glutathione prevents cytolethality of monomethylarsonic acid. , 2004, Toxicology and applied pharmacology.

[14]  M. Bates,et al.  Case-control study of bladder cancer and exposure to arsenic in Argentina. , 2004, American journal of epidemiology.

[15]  Thomas J. Smith,et al.  Arsenic methylation and bladder cancer risk in Taiwan , 2003, Cancer Causes & Control.

[16]  Craig Steinmaus,et al.  Case-control study of bladder cancer and drinking water arsenic in the western United States. , 2003, American journal of epidemiology.

[17]  T. Rossman.  Mechanism of arsenic carcinogenesis: an integrated approach. , 2003, Mutation research.

[18]  M. Ando,et al.  Urinary Arsenic Species in Arsenic-Affected Area of West Bengal, India (Part II) , 2003 .

[19]  B. Walsh,et al.  Polymorphisms in the human monomethylarsonic acid (MMA V) reductase/hGSTO1 gene and changes in urinary arsenic profiles. , 2003, Chemical research in toxicology.

[20]  W. Jędrzejczak.  Arsenic trioxide in the treatment of acute promyelocytic leukemia , 2003 .

[21]  E. Silbergeld,et al.  Variability in human metabolism of arsenic. , 2003, Environmental research.

[22]  H. Jinno,et al.  Functional characterization of two variant human GSTO 1-1s (Ala140Asp and Thr217Asn). , 2003, Biochemical and biophysical research communications.

[23]  Y. Hsueh,et al.  Determinants of inorganic arsenic methylation capability among residents of the Lanyang Basin, Taiwan: arsenic and selenium exposure and alcohol consumption. , 2003, Toxicology letters.

[24]  D. DeMarini,et al.  Methylated trivalent arsenicals as candidate ultimate genotoxic forms of arsenic: Induction of chromosomal mutations but not gene mutations , 2003, Environmental and molecular mutagenesis.

[25]  I. Jaspers,et al.  The role of biomethylation in toxicity and carcinogenicity of arsenic: a research update. , 2002, Environmental health perspectives.

[26]  M. Ando,et al.  Urinary arsenic species in an arsenic‐affected area of West Bengal, India , 2002 .

[27]  M. Kosnett,et al.  Family correlations of arsenic methylation patterns in children and parents exposed to high concentrations of arsenic in drinking water. , 2002, Environmental health perspectives.

[28]  J. B. Simeonsson,et al.  A NovelS-Adenosyl-l-methionine:Arsenic(III) Methyltransferase from Rat Liver Cytosol* , 2002, The Journal of Biological Chemistry.

[29]  D. L. Le Couteur,et al.  Immunohistochemistry of Omega Class Glutathione S-Transferase in Human Tissues , 2001, Journal of Histochemistry and Cytochemistry.

[30]  T. Ley,et al.  Sudden death among patients with acute promyelocytic leukemia treated with arsenic trioxide. , 2001, Blood.

[31]  D. Liebler,et al.  Human monomethylarsonic acid (MMA(V)) reductase is a member of the glutathione-S-transferase superfamily. , 2001, Chemical research in toxicology.

[32]  M. Vahter,et al.  Role of metabolism in arsenic toxicity. , 2001, Pharmacology & toxicology.

[33]  A. Giri,et al.  Genetic toxicology of a paradoxical human carcinogen, arsenic: a review. , 2001, Mutation research.

[34]  W. Cullen,et al.  Methylated trivalent arsenic species are genotoxic. , 2001, Chemical research in toxicology.

[35]  A. Smith,et al.  Arsenic in drinking water and the prevalence of respiratory effects in West Bengal, India. , 2000, International journal of epidemiology.

[36]  R S Judson,et al.  Complex promoter and coding region beta 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[37]  W. Cullen,et al.  Comparative toxicity of trivalent and pentavalent inorganic and methylated arsenicals in rat and human cells , 2000, Archives of Toxicology.

[38]  M. Vahter.  Genetic polymorphism in the biotransformation of inorganic arsenic and its role in toxicity. , 2000, Toxicology letters.

[39]  Rudolfs K. Zalups,et al.  Molecular biology and toxicology of metals , 2000 .

[40]  H. Aposhian,et al.  Enzymatic reduction of arsenic compounds in mammalian systems: the rate-limiting enzyme of rabbit liver arsenic biotransformation is MMA(V) reductase. , 1999, Chemical research in toxicology.

[41]  D. Menzel,et al.  Arsenic disrupts cellular levels of p53 and mdm2: a potential mechanism of carcinogenesis. , 1999, Biochemical and biophysical research communications.

[42]  M. Vahter.  Species differences in the metabolism of arsenic compounds , 1994 .

[43]  A. Smith,et al.  Arsenic ingestion and internal cancers: a review. , 1992, American journal of epidemiology.

[44]  J. G. Farmer,et al.  Use of human metabolic studies and urinary arsenic speciation in assessing arsenic exposure , 1991, Bulletin of environmental contamination and toxicology.

[45]  J. Lubin,et al.  Relation of arsenic exposure to lung cancer among tin miners in Yunnan Province, China. , 1989, British journal of industrial medicine.

[46]  T. Kuo,et al.  ARSENIC AND CANCERS , 1988, The Lancet.

[47]  B. Lind,et al.  Concentrations of arsenic in urine of the general population in Sweden. , 1986, The Science of the total environment.

[48]  C. J. Chen,et al.  Malignant neoplasms among residents of a blackfoot disease-endemic area in Taiwan: high-arsenic artesian well water and cancers. , 1985, Cancer research.

[49]  R. Lauwerys,et al.  Carcinogenicity, teratogenicity and mutagenicity of arsenic. , 1980, Mutation research.